Orgenesis has signed a co-development agreement with Accelix to integrate advanced optic technologies, cartridges, and software onto POCare platform.
Cell and gene therapy company, Orgenesis, has signed a co-development agreement with Accelix, a company that provides assay migration and delivery platform for on-demand process analytics, it was announced in an Oct. 16, 2019 press release.
Under the terms of the agreement, Orgenesis will be afforded the opportunity of integrating Accellix’s proprietary optic system, cartridges, reagents, and software into its Point of Care (POCare) cellular therapy processing services and platform. By amalgamating these systems and services, it is hoped that further advancement of Orgenesis’ quality control systems will be achieved.
“By partnering with Accellix and integrating its advanced optic technologies, cartridges, and software, we believe that this will advance Orgenesis’ processing capabilities for different types of cells for our POCare services and platform,” said Vered Caplan, CEO of Orgenesis, in the press release. “We believe the Orgenesis POCare platform can deliver a transformative option to the cell and gene therapy market that will lower costs in order to potentially bring our autologous therapies to patients in a cost effective, high quality, and scalable manner.”
Financial details of the agreement were not disclosed.
